Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
Regulatory
FDA’s Approval of New Keytruda Indication Yields Fresh Treatment Option for ‘Gigantic Group of Patients’ With Melanoma
The FDA’s recent greenlight of a new Keytruda indication gives a large group of patients with melanoma access to a treatment option that they didn’t previously have, says an expert from the UPMC Hillman Cancer Center.
FDA grants priority review to tebentafusp for metastatic uveal melanoma
Tebentafusp-tebn (Kimmtrak, Immunocore) — the only FDA-approved treatment for this indication — is the first T-cell receptor therapeutic to receive regulatory approval.
FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma
The FDA has approved tebentafusp-tebn (Kimmtrak) for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma.